Reproductive Medicine Associates of New York (RMA of New York) is recognized as a global leader in providing the highest-quality, most advanced in vitro fertilization (IVF) technology available today. RMA of New York is at the forefront of groundbreaking research in infertility and reproductive medicine, and is committed to advancing science for the treatment of infertility.
A wide variety of fertility treatments are available for individuals seeking care from an RMA of New York reproductive specialist, and range from basic infertility care to the most progressive techniques in assisted reproductive technology (ART).
RMA of New York has achieved national recognition for clinical excellence and advanced research in the field of reproductive medicine. The RMA New York physicians, nurses, embryologists, and research professionals have published hundreds of scientific journals, clinical abstracts and peer-reviewed articles, and have received awards from Patient Advocacy Organizations, the American Society of Reproductive Medicine, Ivy League Institutions, and several of the top medical schools in the country. They are actively involved in numerous clinical studies and FDA trials, and have partnered with some of the world’s most advanced IVF technology innovators to vastly improve treatment for the millions of individuals currently facing infertility.
To participate in one of our ongoing clinical studies which will improve the means in which treatments are offered, please inquire with our Manager of Scientific Operations, Joseph Lee, at firstname.lastname@example.org or 212-756-5777 ext. 314.
Individuals Considering Pre-Implantation Genetic Testing (Survey):
RMA of NY is excited to participate on a new research study with Stony Brook University and The New School to understand a patient’s decision making process when considering the use of pre-implantation genetic testing (both PGD and PGS) during their IVF treatment cycle.
This anonymous, online survey welcomes patients who have thought about using this technology in the past six months. We are interested in your perspective whether or not you decided to use it. Please visit www.PGTstudy.weebly.com if you are interested in participating. Upon completion of the survey, you will be entered in a raffle to win a $50 Amazon gift card. One winner will be drawn out of every 50 people who complete a questionnaire. An email address is required for entry into the raffle.
Women’s Genetic Signature:
RMA is working with a biotechnology company, Celmatix, on a study focused on the genetic and phenotypic risk factors underlying female infertility. The study’s goal is to discover genetic sequences and/or mutations within female patients which may be linked to their fertility. The findings from the study are expected to alleviate genetic risk factors for a number of fertility issues at an earlier stage and foster better treatment regimens for future IVF patients. To learn more, click here
Single vs. Multiple Embryo Transfer By: Matthew A. Lederman, MD In vitro fertilization (IVF) has evolved dramatically over the last few decades, with more than six million babies now born through assisted reproductive technology. For years, multiple embryos were transferred to the uterus in hopes ...READ MORE
to receive all the latest News, Events & MORE!